Immunology/Inflammation(免疫及炎症)
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
Products for Immunology/Inflammation
- 5-Lipoxygenase(10)
- Papain(1)
- PGDS(1)
- PGE synthase(24)
- SIKs(11)
- IκB/IKK(64)
- AP-1(6)
- KEAP1-Nrf2(65)
- NOD1(1)
- TLR(139)
- NF-κB(235)
- Interleukin Related(167)
- 15-lipoxygenase(2)
- Others(63)
- Aryl Hydrocarbon Receptor(35)
- CD73(14)
- Complement System(57)
- Galectin(12)
- IFNAR(25)
- NO Synthase(74)
- NOD-like Receptor (NLR)(50)
- STING(104)
- Reactive Oxygen Species(454)
- Apoptosis(780)
- FKBP(20)
- eNOS(5)
- iNOS(29)
- nNOS(20)
- Glutathione(55)
- Adaptive Immunity(209)
- Allergy(124)
- Arthritis(34)
- Autoimmunity(179)
- Gastric Disease(95)
- Immunosuppressants(37)
- Immunotherapeutics(4)
- Innate Immunity(560)
- Pulmonary Diseases(108)
- Reactive Nitrogen Species(50)
- Reactive Sulfur Species(28)
- Specialized Pro-Resolving Mediators(50)
- Cyclic GMP-AMP Synthase(2)
- BCL6(3)
- CD20(3)
- CD28(1)
- FAP(7)
- PSMA(7)
- Nuclear Factor of activated T Cells (NFAT)(1)
- Glycoprotein VI(1)
- Tim3(2)
- Hapten(1)
- Nectin-4(2)
- Cat.No. 产品名称 Information
-
GC73424
PRT062607 acetate
P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate
PRT062607 acetate是一种口服Syk抑制剂(IC50: 1 nM),可抑制炎症和诱导细胞凋亡。 -
GC73417
CASP8-IN-1
CASP8-IN-1(化合物63-R)是胱天蛋白酶8(CASP8)的选择性抑制剂,IC50为0.7μM。
-
GC73413
ARC186 sodium
ARC186 sodium是一种未偶联的40KDa PEG适体,其序列与0 Avacincaptad pegol ARC1905钠相同。
-
GC73407
STING agonist-26
STING agonist-26 (CF508)是一种非核苷酸小分子STING激动剂。
-
GC73396
PRMT6-IN-3
PRMT6-IN-3(化合物25)是一种选择性PRMT6抑制剂,IC50值为192 nM。
-
GC73371
Enpp/Carbonic anhydrase-IN-2
Enpp/Carbonic anhydrase-IN-2是一种强效的Enpp和碳酸酐酶抑制剂,NPP1、NPP2、NPP3、CA-IX、CA-XII的IC50分别为1.13、1.07、0.74、0.33、0.68。
-
GC73355
STAT3-SH2 domain inhibitor 1
STAT3-SH2 domain inhibitor 1是STAT3(STAT3-SH2结构域)的强效Src同源2(SH2)结构域抑制剂,Kd值为1.57μM。
-
GC73328
ODN TTAGGG sodium
ODN A151 sodium
ODN TTAGGG sodium,抑制性寡核苷酸(ODN),是一种TLR9, AIM2和cGAS拮抗剂。 -
GC73327
ODN M362 sodium
ODN M362 sodiumC类寡脱氧核苷酸是TLR-9激动剂,可用作疫苗佐剂。
-
GC73326
ODN D-SL03 sodium
ODN D-SL03 sodium是C类CpG寡核苷酸,可诱导刺激pbmc产生高水平的IFN-α。
-
GC73325
ODN D-SL01 sodium
ODN D-SL01 sodium是B类CpG ODN (oligodeoxynucleotide),是一种TLR9激动剂。
-
GC73324
ODN 24991 sodium
ODN 24991 sodium鸟嘌呤修饰的抑制性寡核苷酸(INH-ODN)是一种TLR3、TLR7和TLR9(Toll样受体)抑制剂,其亲本是INH-ODN2088。
-
GC73323
ODN 24987 sodium
ODN 24987 sodium是一种鸟嘌呤修饰的抑制寡核苷酸(ODN),靶向TLR9。
-
GC73322
ODN 24888 sodium
ODN 24888 sodium是鸟嘌呤修饰的抑制性寡核苷酸(INH-ODN)。
-
GC73321
ODN 2336 sodium
ODN 2336 sodium是一种a类CpG ODN(寡脱氧核苷酸),是一种强效的TLR9激动剂。
-
GC73320
ODN 2216 sodium
ODN 2216 sodium是人类特异性TLR9(toll样受体9)配体或激动剂。
-
GC73319
FITC-labeled ODN 2216 sodium
FITC-labeled ODN 2216 sodium是人类特异性TLR9 toll样受体9配体或激动剂。
-
GC73318
ODN 2007 sodium
ODN 2007 sodium是B类CpG ODN (oligodeoxynucleotide),是toll样受体(Toll-like receptor, TLR)配体。
-
GC73317
ODN 1585 sodium
ODN 1585 sodium是IFN和TNFα产生的强效诱导剂。
-
GC73313
PI3Kα-IN-9
PI3Kα-IN-9(化合物27)是一种选择性、长效和口服活性的PI3Kα抑制剂,对PI3Kα、PI3Kγ、PI3Kδ和PI3Kβ的IC50值分别为4.4、128、146和153 nM。
-
GC73311
STAT3-IN-13
STAT3-IN-13(化合物6f)是一种有效的STAT3抑制剂。
-
GC73309
Anti-melanoma agent 1
Anti-melanoma agent 1(化合物5m)是一种抗黑色素瘤药物,可诱导细胞凋亡。
-
GC73301
5-Aminosalicylic acid-d3
Mesalamine-d3; 5-ASA-d3; Mesalazine-d3
5-Aminosalicylic acid-d3是氘标记的5-氨基水杨酸。 -
GC73294
F5446
F5446(化合物1)是SUV39H1金属转移酶的选择性小分子抑制剂。
-
GC73288
CDK8-IN-13
CDK8-IN-13是一种强效、选择性和口服活性的CDK8抑制剂,IC50值为51.9nM。
-
GC73274
EGFR T790M/L858R-IN-2
EGFR T790M/L858R-IN-2是一种有效的选择性EGFRT790M/L858R抑制剂,对EGFRT790M/L858R和EGFR WT的IC50值分别为3.5和1290 nM。
-
GC73272
PARP-1-IN-3
PARP-1-IN-3苯甲酰胺衍生物是一种强效的PARP-1抑制剂,PARP-1和PARP-2的IC50值分别为0.25 nM和2.34 nM。
-
GC73269
ABBV-467
ABBV-467是一种选择性MCL-1抑制剂(Ki: <0.01 nM)。
-
GC73268
PH14
PH14是PI3K/HDAC双抑制剂,对PI3Kα和HDAC3的IC50值分别为20.3 nM和24.5 nM。
-
GC73243
Nrf2-IN-3
Nrf2-IN-3(化合物R16)是一种Nrf2抑制剂。
-
GC73237
BWA-522
BWA-522是一种口服小分子蛋白靶向嵌合体(PROTACs),对AR-FL和AR-V7具有显著的降解作用。
-
GC73234
MY-673
MY-673是抑制微管蛋白聚合的秋水仙素结合位点抑制剂(CBSI)。
-
GC73232
PRDX1-IN-1
PRDX1-IN-1是PRDX1的选择性抑制剂,IC50值为0.164μM。
-
GC73225
ROS-generating agent 1
ROS-generating agent 1(化合物2c)共价修饰TrxR的Sec-498残基生成ROS。
-
GC73212
TH-6
TH-6是一种强效的HDAC抑制剂,HDAC1、HDAC2、HDAC3、HDAC6、HDAC8的IC50分别为0.115、0.135、0.242、0.138、2.120µM。
-
GC73210
MTR-106
MTR-106是一种强效的口服活性G-四链体稳定剂和RNA聚合酶I抑制剂。
-
GC73199
M47
M47是一种小分子,选择性地破坏隐色素1 (CRY1)的稳定性,并增加细胞核中CRY1的降解。
-
GC73198
PSMA I&T
PSMA I&T是前列腺特异性膜抗原(PSMA)的有效抑制剂。
-
GC73188
SFI003
SFI003是一种SRSF3抑制剂,通过SRSF3/DHCR24/ROS轴驱动CRC细胞凋亡,在体外和体内均表现出强大的抗肿瘤作用。
-
GC73186
STING-IN-6
STING-IN-6(化合物50)是一种有效的STING抑制剂,pIC50为8.9。
-
GC73180
Vidutolimod sodium
CMP-001 sodium
Vidutolimod sodium是一个CpG-A寡脱氧核苷酸。 -
GC73166
U7D-1
U7D-1是一流的有效和选择性USP7(泛素特异性蛋白酶7)PROTAC降解剂,在RS4;11细胞中的DC50为33 nM。
-
GC73159
KTX-582
KTX-582是一种有效的IRAK4降解剂,IRAK4和Ikaros的DC50值分别为4nM和5nM。
-
GC73144
K284-6111
K284-6111是一种对蛋白质几丁质酶3样1(CHI3L1)具有口服活性的抑制剂。
-
GC73138
PBENZ-DBRMD
PBENZ-DBRMD是一种强效的碘三碱脱碘酶3型(DIO3)抑制剂。
-
GC73137
Nenocorilant
NenocorilantKi值为0.15 nM的强效口服活性糖皮质激素受体(GR)拮抗剂。
-
GC73136
VPC-70063
VPC-70063是一种强效的Myc-Max抑制剂,抑制Myc-Max转录活性的IC50值为8.9μM。
-
GC73135
Glu-urea-Glu-NHS ester
Glu-urea-Glu-NHS ester是Glu-尿素-Glu的活化N-羟基琥珀酰胺(NHS)酯,可用作与前列腺特异性膜抗原(PSMA)抑制剂连接的药效团。
-
GC73133
Misetionamide
GP-2250
Misetionamide是一种口服的类似恶硫嗪的化合物。 -
GC73129
SIAIS164018 hydrochloride
SIAIS164018 hydrochloride是一种基于protac的ALK和EGFR降解剂,ALK和ALK G1202R的IC50值分别为2.5 nM和6.6 nM。